Literature DB >> 17901399

Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities.

Marta Magatti1, Silvia De Munari, Elsa Vertua, Lucia Gibelli, Georg S Wengler, Ornella Parolini.   

Abstract

Cells derived from the amniotic membrane of human placenta have been receiving particular attention because of their stem cell potentiality and immunomodulatory properties, which make them an attractive candidate source for cell therapy approaches. In this study, we isolated cells from the mesenchymal region of amnion and identified two subpopulations discordant for expression of the HLA-DR, CD45, CD14, and CD86 cellular markers. We therefore refer to the unfractionated cell population derived from this region as amniotic mesenchymal tissue cells (AMTC). We studied the suppressive and stimulatory characteristics of the unfractionated, HLA-DR-positive, and HLA-DR-negative AMTC populations and demonstrated that all three fail to induce an allogeneic T-cell response. However, unfractionated AMTC, which could inhibit T-cell allogeneic proliferation responses, induced proliferation of T cells stimulated via the T-cell receptor (TcR), in a cell-cell contact setting. We have shown that this stimulatory capacity can be attributed to the HLA-DR-positive AMTC subpopulation. Indeed, even though the HLA-DR-positive AMTC fraction surprisingly failed to induce proliferation of resting allogeneic T cells, they could cause strong proliferation of anti-CD3-primed allogeneic T cells. This stimulatory effect was not observed using the HLA-DR-negative AMTC fraction. The revelation that human amniotic mesenchyme possesses cell populations with both suppressive and stimulatory properties sheds additional light on the immunomodulatory functions of this tissue and may contribute to the clarification of some ongoing controversies associated with mesenchymal stromal cells of other sources, such as the presence of HLA-DR-positive cells and the suppressive versus stimulatory properties of these cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901399     DOI: 10.1634/stemcells.2007-0491

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  61 in total

1.  Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate.

Authors:  A Poloni; G Maurizi; F Serrani; S Mancini; G Discepoli; A L Tranquilli; R Bencivenga; P Leoni
Journal:  Cell Prolif       Date:  2011-12-14       Impact factor: 6.831

2.  In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells.

Authors:  Sveva Bollini; Michela Pozzobon; Muriel Nobles; Johannes Riegler; Xuebin Dong; Martina Piccoli; Angela Chiavegato; Anthony N Price; Marco Ghionzoli; King K Cheung; Anna Cabrelle; Paul R O'Mahoney; Emanuele Cozzi; Saverio Sartore; Andrew Tinker; Mark F Lythgoe; Paolo De Coppi
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

3.  Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes.

Authors:  Changhui Zhou; Bo Yang; Yi Tian; Hongliang Jiao; Wendi Zheng; Jian Wang; Fangxia Guan
Journal:  Cell Immunol       Date:  2011-09-29       Impact factor: 4.868

4.  Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.

Authors:  H Karlsson; T Erkers; S Nava; S Ruhm; M Westgren; O Ringdén
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

5.  Placenta-derived stem cells: new hope for cell therapy?

Authors:  Marco Evangelista; Maddalena Soncini; Ornella Parolini
Journal:  Cytotechnology       Date:  2008-09-28       Impact factor: 2.058

6.  Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers.

Authors:  Giampiero La Rocca; Rita Anzalone; Simona Corrao; Francesca Magno; Tiziana Loria; Melania Lo Iacono; Antonino Di Stefano; Pantaleo Giannuzzi; Lorenzo Marasà; Francesco Cappello; Giovanni Zummo; Felicia Farina
Journal:  Histochem Cell Biol       Date:  2008-10-03       Impact factor: 4.304

7.  Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.

Authors:  Karen Bieback; Irena Brinkmann
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

8.  Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).

Authors:  O Parolini; F Alviano; A G Betz; D W Bianchi; C Götherström; U Manuelpillai; A L Mellor; R Ofir; P Ponsaerts; S A Scherjon; M L Weiss; S Wolbank; K J Wood; C V Borlongan
Journal:  Placenta       Date:  2011-05-14       Impact factor: 3.481

9.  Role of amniotic fluid mesenchymal cells engineered on MgHA/collagen-based scaffold allotransplanted on an experimental animal study of sinus augmentation.

Authors:  Paolo Berardinelli; Luca Valbonetti; Aurelio Muttini; Alessandra Martelli; Renato Peli; Vincenzo Zizzari; Delia Nardinocchi; Michele Podaliri Vulpiani; Stefano Tetè; Barbara Barboni; Adriano Piattelli; Mauro Mattioli
Journal:  Clin Oral Investig       Date:  2012-10-14       Impact factor: 3.573

10.  Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.

Authors:  S Jyothi Prasanna; Divya Gopalakrishnan; Shilpa Rani Shankar; Anoop Babu Vasandan
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.